Novocure To Raise $300M On NASDAQ

September 2, 2015 | The Israeli company marketing a device for the treatment of brain tumors using electric fields, Novocure announced that it will issue an IPO on NASDAQ. The company hopes to raise $300 million at a company valuation of $1 billion, after money. The IPO is being underwritten by JPMorgan, Deutsche Bank and Evercore. Novocure’s electric field therapy for brain tumors has been approved for marketing by the US Food & Drug Administration. The technology was developed at the Technion Israel Institute of Technology by Prof. Yoram Palti.